Condition: B-cell Acute Lymphoblastic Leukemia · Sponsor: Juventas Cell Therapy Ltd.
This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
This description comes directly from the study's public registry record.
Hui Ding · +86-010-65960098 · dinghui@juventas.cn
Always discuss trial participation with your own doctor first.
| The Second Hospital of Anhui Medical University | Hefei, Anhui, China | Not Yet Recruiting |
| Children's Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Guangzhou Women and Children's Medical Center | Guangzhou, Guangdong, China | Recruiting |
| Nanfang Hospital | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Union Hospital Tongji Medical College Huazhong University of Science of Technology | Wuhan, Hubei, China | Not Yet Recruiting |
| Children's Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou, Jiangsu, China | Recruiting |
| The First Affilicated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05667506